Drug/Small Molecule:
duloxetine

last updated 08/10/2011

Dutch Pharmacogenetics Working Group Guideline for duloxetine and CYP2D6

Summary

There are currently no dosing recommendations for duloxetine based on CYP2D6 genotype.

Annotation

The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for duloxetine based on CYP2D6 genotypes [Article:21412232]. They conclude that there are no recommendations at this time.

Phenotype (Genotype) Therapeutic Dose Recommendation Level of Evidence Clinical Relevance
PM (two inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) alleles) No recommendation. Data on file. Clinical effect (not statistically significant difference).
IM (two decreased-activity (*9, *10, *17, *29, *36, *41) alleles or carrying one active (*1, *2, *33, *35) and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele, or carrying one decreased-activity (*9, *10, *17, *29, *36, *41) allele and one inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) allele) No recommendation. No evidence. --
UM (a gene duplication in absence of inactive (*3-*8, *11-*16, *19-*21, *38, *40, *42) or decreased-activity (*9, *10, *17, *29, *36, *41) alleles) No recommendation. No evidence. --

PharmGKB has no annotated drug labels with pharmacogenomic information for this drug/small molecule. If you know of a drug label with PGx, send us a message.

Links to Unannotated Labels

These links are to labels associated with duloxetine that have not been annotated by PharmGKB.

  1. DailyMed - DrugLabel PA166105010

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP2C19 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *3 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *17 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *3 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *4 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *5 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *10 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *17 N/A N/A N/A
No VIP available No VIP available VA CYP2D6 *41 N/A N/A N/A
No VIP available CA VA
rs167770 113879562G>A, 20374708G>A, 23338C>T, 271-848C>T
G > A
Intronic
No VIP available CA VA
rs324023 113885395T>C, 17505A>G, 20380541T>C, 270+5175A>G
T > C
Intronic
No VIP available CA VA
rs324026 -35-168G>A, 113891042C>T, 11858G>A, 20386188C>T
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs6313 102C>T, 160+869C>T, 28449940G>A, 47469940G>A, 6230C>T, HTR2A:102C>T, HTR2A:T102C, Ser34=
G > A
Intronic
Ser34Ser
No VIP available CA VA
rs963468 113862887G>A, 20358033G>A, 40013C>T, 526+3375C>T
G > A
Intronic
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • (+-)-duloxetine
  • Duloxetine HCl
  • Duloxetine Hydrochloride
Trade Names
  • Cymbalta
  • Yentreve
Brand Mixture Names

PharmGKB Accession Id:
PA10066

Description

Duloxetine (brand names Cymbalta, Yentreve, and in parts of Europe, Xeristar or Ariclaim) is a drug which primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), pain related to diabetic peripheral neuropathy and in some countries stress urinary incontinence (SUI). It is manufactured and marketed by Eli Lilly and Company.

Duloxetine has not yet been FDA approved for stress urinary incontinence or for fibromyalgia.

Duloxetine is a selective SNRI (selective serotonin-norepinephrine reuptake inhibitor). Duloxetine is a systemic drug therapy which affects the body as a whole. Known also under the code name LY248686, it is a potent dual reuptake inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE), possessing comparable affinities in binding to NE- and 5-HT transporter sites. It is a less potent inhibitor of dopamine reuptake.

Source: Drug Bank

Indication

For the acute and maintenance treatment of major depressive disorder (MDD), as well as acute management of generalized anxiety disorder. Also used for the management of neuropathic pain associated with diabetic peripheral neuropathy, and fibromyalgia. Has been used in the management of moderate to severe stress urinary incontinence (SUI) in women.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors. The antidepressant and pain inhibitory actions of duloxetine are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS. The mechanism of action of duloxetine in SUI has not been determined, but is thought to be associated with the potentiation of serotonin and norepinephrine activity in the spinal cord, which increases urethral closure forces and thereby reduces involuntary urine loss.

Source: Drug Bank

Pharmacology

Duloxetine is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SSNRIs) and primarily targets major depressive disorders (MDD) and stress urinary incontinence (SUI). Duloxetine is also used to treat pain and tingling caused by diabetic neuropathy (damage to nerves that can develop in people who have diabetes). Known also as LY248686, it is a potent dual inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) reuptake, possessing comparable affinities in binding to NE and 5-HT transport sites. Interestingly, its behavior contrasts to most other dual-reuptake inhibitors. Furthermore, duloxentine lacks affinity for monoamine receptors within the central nervous system.

Source: Drug Bank

Food Interaction

Food does not affect maximum levels reached, but delays it (from 6 to 10 hours) and total product exposure appears to be reduced by only 10%.|Take without regard to meals.|People taking this product who drink large amounts of alcohol are exposed to a higher risk of liver toxicity.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

The major biotransformation pathways for duloxetine involve oxidation of the naphthyl ring followed by conjugation and further oxidation. Both CYP2D6 and CYP1A2 catalyze the oxidation of the naphthyl ring in vitro. Metabolites found in plasma include 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate. The major circulating metabolites have not been shown to contribute significantly to the pharmacologic activity of duloxetine.

Source: Drug Bank

Protein Binding

Protein binding is greater than 90%.

Source: Drug Bank

Absorption

Orally administered duloxetine hydrochloride is well absorbed.

Source: Drug Bank

Half-Life

12 hours (range 8-17 hours)

Source: Drug Bank

Toxicity

Oral, rat LD 50: 491 mg/kg for males and 279 mg/kg for females. Symptoms of overdose include tremors, convulsions, reduced activity, slow pupillary response, intermittent tremors, and rigidity.

Source: Drug Bank

Route of Elimination

Many additional metabolites have been identified in urine, some representing only minor pathways of elimination. Most (about 70%) of the duloxetine dose appears in the urine as metabolites of duloxetine; about 20% is excreted in the feces.

Source: Drug Bank

Volume of Distribution

  • 1640 L

Source: Drug Bank

Chemical Properties

Chemical Formula

C18H19NOS

Source: Drug Bank

Isomeric SMILES

CNCC[C@@H](c1cccs1)Oc2cccc3c2cccc3

Source: OpenEye

Canonical SMILES

CNCC[C@H](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1

Source: Drug Bank

Average Molecular Weight

297.415

Source: Drug Bank

Monoisotopic Molecular Weight

297.118734925

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

EvidenceGene
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C19
DG No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2D6
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
DRD3
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
HTR2A

Drug Targets

Gene Description
SLC6A2 (source: Drug Bank)
SLC6A3 (source: Drug Bank)
SLC6A4 (source: Drug Bank)

Drug Interactions

Drug Description
duloxetine Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
duloxetine Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
duloxetine Increases the effect/toxicity of duloxetine (source: Drug Bank)
duloxetine Increases the effect/toxicity of duloxetine (source: Drug Bank)
duloxetine Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
duloxetine Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
amitriptyline Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
amitriptyline Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
ciprofloxacin Ciprofloxacin increases the effect/toxicity of duloxetine (source: Drug Bank)
ciprofloxacin Ciprofloxacin increases the effect/toxicity of duloxetine (source: Drug Bank)
desipramine Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
desipramine Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
flecainide Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
flecainide Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of duloxetine (source: Drug Bank)
fluvoxamine Fluvoxamine increases the effect and toxicity of duloxetine (source: Drug Bank)
imipramine Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
imipramine Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
isocarboxazid Possible severe adverse reaction with this combination (source: Drug Bank)
nortriptyline Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
nortriptyline Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
phenelzine Possible severe adverse reaction with this combination (source: Drug Bank)
phenelzine Possible severe adverse reaction with this combination (source: Drug Bank)
propafenone Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
propafenone Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
rasagiline Possible severe adverse reaction with this combination (source: Drug Bank)
rasagiline Possible severe adverse reaction with this combination (source: Drug Bank)
thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
tranylcypromine Possible severe adverse reaction with this combination (source: Drug Bank)
tranylcypromine Possible severe adverse reaction with this combination (source: Drug Bank)
duloxetine Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
duloxetine Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
duloxetine Fluvoxamine increases the effect and toxicity of duloxetine (source: Drug Bank)
duloxetine Fluvoxamine increases the effect and toxicity of duloxetine (source: Drug Bank)
duloxetine Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
duloxetine Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
duloxetine Possible severe adverse reaction with this combination (source: Drug Bank)
duloxetine Possible severe adverse reaction with this combination (source: Drug Bank)
duloxetine Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
duloxetine Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
duloxetine Possible severe adverse reaction with this combination (source: Drug Bank)
duloxetine Possible severe adverse reaction with this combination (source: Drug Bank)
duloxetine Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
duloxetine Possible increase in the levels of this agent when used with duloxetine (source: Drug Bank)
duloxetine Possible severe adverse reaction with this combination (source: Drug Bank)
duloxetine Duloxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank)
duloxetine Duloxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank)
duloxetine Duloxetine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Duloxetine is initiated, discontinued, or dose changed. (source: Drug Bank)
duloxetine Duloxetine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Duloxetine is initiated, discontinued, or dose changed. (source: Drug Bank)
duloxetine Terbinafine may reduce the metabolism and clearance of Duloxetine. Consider alternate therapy or monitor for therapeutic/adverse effects of Duloxetine if Terbinafine is initiated, discontinued or dose changed. (source: Drug Bank)
duloxetine The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Duloxetine by decreasing Duloxetine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Duloxetine if Thiabendazole is initiated, discontinued or dose changed. (source: Drug Bank)
duloxetine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
duloxetine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank)
duloxetine Duloxetine may decrease the effect of Tramadol by decreasing active metabolite production. Increased risk of serotonin syndrome. Monitor for Tramadol efficacy and symptoms of serotonin syndrome. (source: Drug Bank)
duloxetine Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies. (source: Drug Bank)
duloxetine Increased risk of serotonin syndrome. The 2D6 inhibitor, Trazodone, may also increase the efficacy of Duloxetine by decreasing Duloxetine metabolism and clearance. Monitor for symptoms of serotonin syndrome and changes in Duloxetine efficacy if Trazodone is initiated, discontinued or dose changed. (source: Drug Bank)
duloxetine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
duloxetine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
duloxetine The CNS depressants, Triprolidine and Duloxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. (source: Drug Bank)
duloxetine The CNS depressants, Triprolidine and Duloxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. (source: Drug Bank)
duloxetine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. (source: Drug Bank)
duloxetine Use of two serotonin modulators, such as zolmitriptan and duloxetine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. (source: Drug Bank)

Curated Information ?

Publications related to duloxetine: 22

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Serotonin toxicity from antidepressant overdose and its association with the T102C polymorphism of the 5-HT2A receptor. The pharmacogenomics journal. 2014. Cooper J M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. The pharmacogenomics journal. 2013. Brandl E J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. PLoS computational biology. 2012. Duke Jon D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder. The pharmacogenomics journal. 2012. Perlis R H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Augmentative effects of fluvoxamine on duloxetine plasma levels in depressed patients. Pharmacopsychiatry. 2011. Paulzen M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coprescription of tamoxifen and medications that inhibit CYP2D6. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Sideras Kostandinos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Acute and Chronic Pain Management in Fibromyalgia: Updates on Pharmacotherapy. American journal of therapeutics. 2010. Hsu Eric S. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug discovery. Repurposing with a difference. Science (New York, N.Y.). 2009. Boguski Mark S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biological psychiatry. 2009. Perlis Roy H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clinical pharmacology and therapeutics. 2009. Zhang Y, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS drugs. 2009. Carter Natalie J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation. Clinical pharmacokinetics. 2009. Lobo Evelyn D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The influence of smoking on the serum level of duloxetine. Pharmacopsychiatry. 2008. Fric M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clinical pharmacokinetics. 2008. Lobo Evelyn D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects. British journal of clinical pharmacology. 2007. Chan Clark, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. British journal of pharmacology. 2007. Gillman P K. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. Journal of clinical psychopharmacology. 2007. Preskorn Sheldon H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects. Clinical pharmacokinetics. 2007. Tianmei Si, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Current pharmaceutical design. 2005. Bymaster Frank P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clinical pharmacology and therapeutics. 2003. Skinner Michael H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2001. Bymaster F P, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
54868-5215-2
DrugBank:
DB00476
ChEBI:
36795
KEGG Drug:
D01179
PubChem Compound:
60835
PubChem Substance:
46507937
704934
IUPHAR Ligand:
202
ChemSpider:
54822
Therapeutic Targets Database:
DAP000494
FDA Drug Label at DailyMed:
81a06b90-50d3-40c1-98ca-0e344c76b2c4

Clinical Trials

These are trials that mention duloxetine and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.